Valravillon

Researchers are evaluating the effectiveness and safety of RO7837195 in adults with moderately to severely active ulcerative colitis who have not responded well or tolerated conventional or advanced treatments. This Phase IIb study aims to compare RO7837195 to a placebo during the initial treatment phase and then monitor all participants receiving the active drug to assess clinical remission at 12 weeks. The study includes a screening period lasting up to 5 weeks, followed by a 12-week induction phase where participants receive either RO7837195 or a matching placebo according to a specified schedule. After this induction phase, all participants enter a 40-week active treatment extension where they receive RO7837195 regardless of their earlier response. A safety follow-up period occurs after the last dose to continue monitoring participant health. Participants will undergo assessments throughout the study to measure clinical remission at week 12 and to monitor safety and pharmacokinetics. Researchers will collect data on symptoms, treatment effects, and any side effects experienced. The total participation involves multiple phases designed to carefully evaluate the long-term impact and safety of RO7837195 in ulcerative colitis management.

Researchers are evaluating a new blood test called Guardant Reveal designed to detect cancer recurrence in people treated for early-stage solid tumors. The study aims to show how well this test can identify cancer returning and link its results to clinical outcomes. This will help understand the test's usefulness in real-world healthcare settings where costs are important. The types of cancers studied include bladder, lung, breast, melanoma, esophageal, gastric, pancreatic, head and neck, ovarian, endometrial, renal, and rectal cancers. Participants will have blood samples taken at the start and during their regular follow-up visits for up to five years. The Guardant Reveal test, which looks for minimal residual disease, will be used to analyze these blood samples to detect any signs of cancer returning. This study includes various groups based on specific tumor types and stages, such as muscle invasive carcinomas, non-small cell lung cancer, high-risk breast cancer, melanoma, gastrointestinal cancers, and others. Each group follows standard care treatments, and the study observes how the new test performs alongside usual monitoring. During the study, participants will provide blood samples coinciding with their routine follow-up care, and their clinical information will be collected and shared with researchers in a de-identified way. The main outcome measured is the time until distant cancer recurrence over three years. The study tracks participants for up to five years to assess the test's ability to detect recurrence early, aiming to improve monitoring and management of these cancers.